Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections

Journal of Medical Microbiology

Volumn 54, Issue 7, 2005, Pages 647-653

  Yordanov, M ^a   Dimitrova, P ^a   Patkar, S ^b   Falcocchio, S ^c   Xoxi, E ^c   Saso, L ^c   Ivanovska, N ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^b NOVOZYMES A S   (Denmark)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; GAMMA INTERFERON; IBOGAINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; COLONY FORMING UNIT; DELAYED HYPERSENSITIVITY; EPITHELIUM CELL; FEMALE; GASTROINTESTINAL INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; LIPOLYSIS; MALE; MORTALITY; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PRIORITY JOURNAL;

ADHESIVENESS; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BRAIN; CANDIDA ALBICANS; CANDIDIASIS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HYPERSENSITIVITY, DELAYED; IBOGAINE; INJECTIONS, INTRAPERITONEAL; KIDNEY; LIPASE; LIVER; MALE; MICE; MICE, INBRED BALB C; SPLEEN;

EID: 21244444294     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.45919-0     Document Type: Article

References (35)

1. Andriole, V. T. (1999). The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 44, 151-162.
2. Baumann, M. H., Rothman, R. B., Pablo, J. P. & Mash, D. C. (2001a). In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 297, 531-539.
3. Baumann, M. H., Pablo, J., Ali, S. F., Rothman, R. B. & Mash, D. C. (2001b). Comparative neuropharmacology of ibogaine and its O desmethyl metabolite, noribogaine. Alkaloids Chem Biol 56, 79-113.
4. Bennett, D. E., McCreary, C. E. & Coleman, D. C. (1998). Genetic characterization of a phospholipase C gene from Candida albicans: presence of homologous sequences in Candida species other than Candida albicans. Microbiology 144, 55-72.
5. Cox, G. M., McDade, H. C., Chen, S. C. & 8 other authors (2001). Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol 39, 166-175.
6. Fidel, P. L., Jr (2004). History and new insights into host defense against vaginal candidiasis. Trends Microbiol 12, 220-227.
7. Fidel, P. L., Jr, Vazquez, J. A. & Sobel, J. D. (1999). Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12, 80-96.
8. Fu, Y., Ibrahim, A. S., Fonzi, W., Zhou, X., Ramos, C. F. & Ghannoum, M. A. (1997). Cloning and characterization of a gene (LIP1) which encodes a lipase from the pathogenic yeast Candida albicans. Microbiology 143, 331-340.
9. Ghannoum, M. A. (2000). Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 13, 122-143.
10. Glick, S. D., Maisonneuve, I. M. & Szumlinskl, K. K. (2000). 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of anti-addictive efficacy, toxicity, and mechanisms of action. Ann N Y Acad Sci 914, 369-386.
11. Click, S. D., Maisonneuve, I. M. & Szumlinski, K. K. (2001). Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem Biol 56, 39-53.
12. Hanel, H., Kirsch, R., Schmidts, H. L. & Kottmann, H. (1995). New systematically active antimycotics from the beta-blocker category. Mycoses 38, 251-264.
13. Hough, L. B., Pearl, S. M. & Glick, S. D. (1996). Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sci 58, PL119-PL122.
14. Hough, L. B., Bagal, A. A. & Glick, S. D. (2000). Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. Methods Find Exp Clin Pharmacol 22, 77-81.
15. House, R. V., Thomas, P. T. & Bhargava, H. N. (1995). Comparison of the hallucinogenic indole alkaloids ibogaine and harmaline for potential immunomodulatory activity. Pharmacology 51, 56-65.
16. Hube, B., Stehr, F., Bossenz, M., Mazur, A., Kretschmar, M. & Schafer, W. (2000). Secreted lipases of Candida albicans: cloning, characterisation and expression analysis of a new gene family with at least ten members. Arch Microbiol 174, 362-374.
17. Hube, B., Hess, D., Baker, C. A., Schaller, M., Schafer, W. & Dolan, J. W. (2001). The role and relevance of phospholipase D1 during growth and dimorphism of Candida albicans. Microbiology 147, 879-889.
18. Kariba, R. M., Houghton, P. J. & Yenesew, A. (2002). Antimicrobial activities of a new schizozygane indoline alkaloid from Schizozygia coffaeoides and the revised structure of isoschizogaline. J Nat Prod 65, 566-569.
19. Komshian, S. V., Uwaydah, A. K., Sobel, J. D. & Crane, L. R. (1989). Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11, 379-390.
20. Leidich, S. D., Ibrahim, A. S., Fu, Y. & 8 other authors (1998). Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem 273, 26078-26086.
21. Mash, D. C., Staley, J. K., Pablo, J. P., Holohean, A. M., Hackman, J. C. & Davidoff, R. A. (1995). Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci Lett 192, 53-56.
22. Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. D., Williams, I. C., Singleton, E. G. & Mayor, M. (2000). Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 914, 394-401.
23. Molinari, H. H., Maisonneuve, I. M. & Glick, S. D. (1996). Ibogaine neurotoxicity: a re-evaluation. Brain Res 737, 255-262.
24. Mukherjee, P. K., Seshan, K. R., Leidich, S. D., Chandra, J., Cole, G. T. & Ghannoum, M. A. (2001). Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo. Microbiology 147, 2585-2597.
25. O'Garra, A., Steinman, L. & Gijbels, K. (1997). CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 9, 872-883.
26. Pfaller, M. A. (1996). Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 22, S89-S94.
27. Portnoy, D. A., Smith, G. A. & Goldfine, H. (1994). Phospholipases C and the pathogenesis of Listeria. Braz J Med Biol Res 27, 357-361.
28. Price, M. F., Wilkinson, I. D. & Gentry, L. O. (1982). Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 20, 7-14.
29. Saffer, L. D. & Schwartzman, J. D. (1991). A soluble phospholipase of Toxoplasma gondii associated with host cell penetration. J Protozool 38, 454-460.
30. Shearer, G. M. (1998). HIV-induced immunopathogenesis. Immunity 9, 587-593.
31. Songer, J. G. (1997). Bacterial phospholipases and their role in virulence. Trends Microbiol 5, 156-161.
32. Sugiyama, Y., Nakashima, S., Mirbod, R, Kanoh, H., Kitajima, Y., Ghannoum, M. A. & Nozawa, Y. (1999). Molecular cloning of a second phospholipase B gene, caPLB2 from Candida albicans. Med Mycol 37, 61-67.
33. Titball, R. W. (1993). Bacterial phospholipases C. Microbiol Rev 57, 347-366.
34. Tsuboi, R., Komatsuzaki, H. & Ogawa, H. (1996). Induction of an extracellular esterase from Candida albicans and some of its properties. Infect Immun 64, 2936-2940.
35. Wenzel, R. P. (1995). Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20, 1531-1534.